Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals.
Erdmann NB, Williams WB, Walsh SR, Grunenberg N, Edlefsen PT, Goepfert PA, Cain DW, Cohen KW, Maenza J, Mayer KH, Tieu HV, Sobieszczyk ME, Swann E, Lu H, De Rosa SC, Sagawa Z, Moody MA, Fox CB, Ferrari G, Edwards RJ, Acharya P, Alam SM, Parks R, Barr M, Tomaras GD, Montefiori DC, Gilbert PB, McElrath MJ, Corey L, Haynes BF, Baden LR; NIAID HVTN 133 Study Group. Erdmann NB, et al. Among authors: de rosa sc. medRxiv [Preprint]. 2024 Mar 18:2024.03.15.24304305. doi: 10.1101/2024.03.15.24304305. medRxiv. 2024. PMID: 38562833 Free PMC article. Preprint.
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies.
Hahn WO, Parks KR, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Woodward Davis AS, Duplessis C, Tomai M, Dey AK, Sagawa ZK, De Rosa SC, Seese A, Siddaramaiah LK, Stamatatos L, Lee WH, Sewall LM, Karlinsey D, Turner HL, Rubin V, Furth S, MacPhee K, Duff M, Corey L, Keefer MC, Edupuganti S, Frank I, Maenza J, Baden LR, Hyrien O, Sanders RW, Moore JP, Ward AB, Tomaras GD, Montefiori DC, Rouphael N, McElrath MJ. Hahn WO, et al. Among authors: de rosa sc. medRxiv [Preprint]. 2024 May 9:2024.05.08.24306957. doi: 10.1101/2024.05.08.24306957. medRxiv. 2024. PMID: 38766048 Free PMC article. Preprint.
Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus.
Edwards KR, Schmidt K, Homad LJ, Kher GM, Xu G, Rodrigues KA, Ben-Akiva E, Abbott J, Prlic M, Newell EW, De Rosa SC, Irvine DJ, Pancera M, McGuire AT. Edwards KR, et al. Among authors: de rosa sc. Cell Rep Med. 2024 May 16:101587. doi: 10.1016/j.xcrm.2024.101587. Online ahead of print. Cell Rep Med. 2024. PMID: 38781964 Free article.
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.
Ober Shepherd BL, Scott PT, Hutter JN, Lee C, McCauley MD, Guzman I, Bryant C, McGuire S, Kennedy J, Chen WH, Hajduczki A, Mdluli T, Valencia-Ruiz A, Amare MF, Matyas GR, Rao M, Rolland M, Mascola JR, De Rosa SC, McElrath MJ, Montefiori DC, Serebryannyy L, McDermott AB, Peel SA, Collins ND, Joyce MG, Robb ML, Michael NL, Vasan S, Modjarrad K; EID-030 Study Group. Ober Shepherd BL, et al. Among authors: de rosa sc. Lancet Microbe. 2024 May 15:S2666-5247(23)00410-X. doi: 10.1016/S2666-5247(23)00410-X. Online ahead of print. Lancet Microbe. 2024. PMID: 38761816 Free article.
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S; HVTN 124 Study Team. Frank I, et al. Among authors: de rosa sc. Lancet HIV. 2024 May;11(5):e285-e299. doi: 10.1016/S2352-3018(24)00036-5. Lancet HIV. 2024. PMID: 38692824 Clinical Trial.
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial.
Miner MD, deCamp A, Grunenberg N, De Rosa SC, Fiore-Gartland A, Bar K, Spearman P, Allen M, Yu PC, Manso B, Frahm N, Kalams S, Baden L, Keefer MC, Scott HM, Novak R, Van Tieu H, Tomaras GD, Kublin JG, McElrath MJ, Corey L, Frank I; HVTN 085 Study Team. Miner MD, et al. Among authors: de rosa sc. EBioMedicine. 2024 Feb;100:104987. doi: 10.1016/j.ebiom.2024.104987. Epub 2024 Feb 1. EBioMedicine. 2024. PMID: 38306894 Free PMC article. Clinical Trial.
The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy.
Jacobson JM, Felber BK, Chen H, Pavlakis GN, Mullins JI, De Rosa SC, Kuritzkes DR, Tomaras GD, Kinslow J, Bao Y, Olefsky M, Rosati M, Bear J, Heptinstall JR, Zhang L, Sawant S, Hannaman D, Laird GM, Cyktor JC, Heath SL, Collier AC, Koletar SL, Taiwo BO, Tebas P, Wohl DA, Belaunzaran-Zamudio PF, McElrath MJ, Landay AL; ACTG 5369 Study Team. Jacobson JM, et al. Among authors: de rosa sc. AIDS. 2024 Jun 1;38(7):963-973. doi: 10.1097/QAD.0000000000003804. Epub 2023 Dec 1. AIDS. 2024. PMID: 38051788 Clinical Trial.
mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RAint TEMRA-like CD8+ T cells in COVID-19 recovered individuals.
Mayer-Blackwell K, Ryu H, Codd AS, Parks KR, MacMillan HR, Cohen KW, Stewart TL, Seese A, Lemos MP, De Rosa SC, Czartoski JL, Moodie Z, Nguyen LT, McGuire DJ, Ahmed R, Fiore-Gartland A, McElrath MJ, Newell EW. Mayer-Blackwell K, et al. Among authors: de rosa sc. Cell Rep Med. 2023 Aug 15;4(8):101149. doi: 10.1016/j.xcrm.2023.101149. Epub 2023 Aug 7. Cell Rep Med. 2023. PMID: 37552991 Free PMC article.
134 results